BridgeBio Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $28.165
- Today's High:
- $29.335
- Open Price:
- $28.4
- 52W Low:
- $5.74
- 52W High:
- $19.945
- Prev. Close:
- $28.53
- Volume:
- 1208429
Company Statistics
- Market Cap.:
- $2.29 billion
- Book Value:
- -7.64
- Revenue TTM:
- $77.78 million
- Operating Margin TTM:
- -565.98%
- Gross Profit TTM:
- $74.21 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -38.24%
- Return on Equity TTM:
- -1789.67%
Company Profile
BridgeBio Pharma Inc had its IPO on 2019-06-27 under the ticker symbol BBIO.
The company operates in the Healthcare sector and Biotechnology industry. BridgeBio Pharma Inc has a staff strength of 392 employees.
Stock update
Shares of BridgeBio Pharma Inc opened at $28.4 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $28.17 - $29.34, and closed at $28.55.
This is a +0.07% increase from the previous day's closing price.
A total volume of 1,208,429 shares were traded at the close of the day’s session.
In the last one week, shares of BridgeBio Pharma Inc have slipped by -6.64%.
BridgeBio Pharma Inc's Key Ratios
BridgeBio Pharma Inc has a market cap of $2.29 billion, indicating a price to book ratio of 123.6828 and a price to sales ratio of 15.0218.
In the last 12-months BridgeBio Pharma Inc’s revenue was $77.78 million with a gross profit of $74.21 million and an EBITDA of $-433695008. The EBITDA ratio measures BridgeBio Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BridgeBio Pharma Inc’s operating margin was -565.98% while its return on assets stood at -38.24% with a return of equity of -1789.67%.
In Q1, BridgeBio Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 7.8%.
BridgeBio Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BridgeBio Pharma Inc’s profitability.
BridgeBio Pharma Inc stock is trading at a EV to sales ratio of 28.7752 and a EV to EBITDA ratio of -6.1605. Its price to sales ratio in the trailing 12-months stood at 15.0218.
BridgeBio Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $625.68 million
- Total Liabilities
- $92.92 million
- Operating Cash Flow
- $12.30 million
- Capital Expenditure
- $12000
- Dividend Payout Ratio
- 0%
BridgeBio Pharma Inc ended 2024 with $625.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $625.68 million while shareholder equity stood at $-1225665000.00.
BridgeBio Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $92.92 million in other current liabilities, 167000.00 in common stock, $-2057455000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $407.37 million and cash and short-term investments were $441.49 million. The company’s total short-term debt was $3,674,000 while long-term debt stood at $1.71 billion.
BridgeBio Pharma Inc’s total current assets stands at $502.90 million while long-term investments were $49.80 million and short-term investments were $34.12 million. Its net receivables were $10.76 million compared to accounts payable of $4.08 million and inventory worth $0.
In 2024, BridgeBio Pharma Inc's operating cash flow was $12.30 million while its capital expenditure stood at $12000.
Comparatively, BridgeBio Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $28.55
- 52-Week High
- $19.945
- 52-Week Low
- $5.74
- Analyst Target Price
- $28.56
BridgeBio Pharma Inc stock is currently trading at $28.55 per share. It touched a 52-week high of $19.945 and a 52-week low of $19.945. Analysts tracking the stock have a 12-month average target price of $28.56.
Its 50-day moving average was $28.57 and 200-day moving average was $16.55 The short ratio stood at 7.29 indicating a short percent outstanding of 0%.
Around 574.6% of the company’s stock are held by insiders while 9099% are held by institutions.
Frequently Asked Questions About BridgeBio Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.